KalVista Pharmaceuticals, Inc. Form 4 Filings

KalVista Pharmaceuticals director Brian JG Pereira reported the disposition of stock options in connection with the company’s merger with Chiesi Farmaceutici. On June 11, 2026, he surrendered multiple fully vested options covering a total of 91,000 shares of common stock to the issuer.

Under the Agreement and Plan of Merger, Chiesi’s subsidiary completed a cash tender offer for all KalVista common shares at $27.00 per share, followed by a merger that made KalVista a wholly owned subsidiary. Options with exercise prices below $27.00 were cancelled and converted into cash rights based on the spread between the merger price and each option’s exercise price, while any options with exercise prices equal to or above $27.00 were cancelled for no consideration.

KalVista Pharmaceuticals director William Fairey reported the disposition to the issuer of three stock option awards in connection with the company’s merger with Chiesi Farmaceutici. On June 11, 2026, options covering 30,000, 10,000, and 17,000 shares of common stock were cancelled, leaving no remaining options from these grants.

Under the Merger Agreement, Chiesi’s subsidiary completed a cash tender offer for all KalVista common shares at $27.00 per share, followed by a merger that made KalVista a wholly owned subsidiary. Each in-the-money option automatically vested and was converted into a cash right based on the difference between the $27.00 Merger Consideration and the option’s exercise price, while any options with exercise prices at or above $27.00 were cancelled for no payment.

KalVista Pharmaceuticals, Inc. chief medical officer Paul K. Audhya reported the disposition of his equity awards in connection with the company’s merger into a subsidiary of Chiesi Farmaceutici S.p.A. On June 11, 2026, his holdings in 150,260 shares of common stock were cancelled.

The filing shows additional dispositions of restricted stock units covering 93,750, 68,750, and 40,000 shares of common stock, as well as stock options over 25,800 shares at $9.28 and 100,000 shares at $24.97 per share. According to the merger agreement, in-the-money options and RSUs became fully vested and were converted into cash based on the $27.00 per-share merger consideration, while options with exercise prices at or above $27.00 were cancelled without payment. Following these transactions, the report shows no remaining holdings for the reporting person.

KalVista Pharmaceuticals director Bethany Sensenig reported the disposition of stock options as part of the company’s merger with Chiesi Farmaceutici. A total of 45,000 options with a per share exercise price of $12.05 were cancelled and converted into a cash right based on the merger consideration of $27.00 per share. Following the transaction, no options from this grant remain outstanding.

KalVista Pharmaceuticals director Patrick Treanor reported the disposition of several stock option grants to the issuer in connection with KalVista’s cash merger with Chiesi Farmaceutici. Under the merger, all KalVista common shares were acquired for $27.00 per share, and his fully vested in-the-money options were cancelled and converted into cash rights based on the spread between this merger price and each option’s exercise price.

KalVista Pharmaceuticals, Inc. Chief Commercial Officer Nicole Sweeny reported the disposition of her equity in connection with the company’s merger into a subsidiary of Chiesi Farmaceutici. On June 11, 2026, she disposed of 59,291 shares of common stock and cancelled multiple restricted stock unit (RSU) awards and stock options back to the issuer.

Under the merger agreement, all outstanding KalVista common shares were acquired via a cash tender offer at $27.00 per share, and unexercised options and RSUs were cancelled in exchange for cash based on this consideration, or cancelled without payment if the option exercise price was at or above $27.00. Following these transactions, Sweeny reports zero shares and zero derivatives owned, reflecting the cash-out of her position as KalVista became a wholly owned subsidiary of Chiesi.

KalVista Pharmaceuticals' Chief Operations Officer, Arif Bilal, reported the cash-out of equity awards tied to the company’s acquisition by Chiesi Farmaceutici. On June 11, 2026, 49,000 restricted stock units and 100,000 stock options were disposed of to the issuer as part of a completed merger.

Under the Merger Agreement, Chiesi’s subsidiary acquired all outstanding KalVista common shares for $27.00 per share in cash, then merged with KalVista, which now operates as a wholly owned subsidiary. Unexercised options with an exercise price below the $27.00 merger consideration and outstanding RSUs were fully vested, cancelled, and converted into cash payments based on formulas set in the agreement, while underwater options were cancelled with no payment.

KalVista Pharmaceuticals director Reid Laurence reported the disposition of a stock option grant in connection with the company’s acquisition by Chiesi Farmaceutici. A stock option covering 17,000 shares of common stock with a per share exercise price of $10.07 was surrendered to the issuer.

Under the merger agreement, a Chiesi subsidiary completed a cash tender offer for all outstanding KalVista common shares at $27.00 per share, after which the subsidiary merged into KalVista on June 11, 2026, making KalVista a wholly owned subsidiary. Per the merger terms, in-the-money options such as this one became fully vested, were cancelled, and converted into the right to receive a cash payment based on the difference between the merger price and the option exercise price, multiplied by the number of option shares. Options with exercise prices at or above $27.00 were cancelled for no consideration.

KalVista Pharmaceuticals director Edward W. Unkart disposed of stock options in connection with the company’s acquisition by Chiesi Farmaceutici. On June 11, 2026, he surrendered a total of 109,000 stock options to the issuer in multiple transactions coded as dispositions to issuer.

According to the merger agreement, Chiesi’s subsidiary completed a cash tender offer for all KalVista common shares at $27.00 per share, after which the merger closed and KalVista became a wholly owned subsidiary. Each outstanding in-the-money option was cancelled and converted into a right to receive cash equal to the spread between the $27.00 consideration and its exercise price, multiplied by the number of underlying shares.

KalVista Pharmaceuticals chief executive officer Benjamin L. Palleiko reported the disposition of his equity in connection with the company’s merger with Chiesi Farmaceutici. A total of 479,989 shares of common stock and multiple restricted stock units and stock options were cancelled and converted into cash rights under the merger terms at a cash price of $27.00 per share for common stock or, for in-the-money options, the cash value of the spread. Following these transactions, the filing shows no remaining reported holdings for these securities.

KalVista Pharmaceuticals chief development officer Christopher Yea reported dispositions of all his equity in connection with the company’s merger with Chiesi Farmaceutici. A tender offer and subsequent merger converted issued and outstanding common shares into cash at $27.00 per share, subject to tax withholding. Yea disposed of 229,918 shares of common stock and multiple restricted stock unit and stock option awards, which were cancelled under the merger terms. Vested options with exercise prices below $27.00 were converted into cash payments based on the spread, while options at or above that price were cancelled without consideration, leaving him with no remaining reported holdings.

KalVista Pharmaceuticals’ Chief Financial Officer Brian Piekos disposed of his equity awards in connection with the company’s cash sale to Chiesi Farmaceutici. He returned 21,661 shares of common stock to the issuer and cancelled 93,750 and 55,000 share restricted stock unit awards.

Pursuant to the merger agreement, Chiesi’s subsidiary completed a cash tender offer for all KalVista common shares at $27.00 per share, after which the acquirer merged with KalVista. Outstanding stock options with exercise prices below the $27.00 merger consideration, including 100,000 options at $11.87 per share, and all RSUs became fully vested and were converted into rights to receive cash, leaving Piekos with no remaining reported holdings.

KalVista Pharmaceuticals chief development officer Christopher Yea reported an option exercise paired with an open-market sale of common stock. He exercised employee stock options to acquire 33,800 shares at an exercise price of $7.07 per share, fully exercising that option grant. On the same date, he sold 33,800 common shares in open-market transactions at a weighted average price of $26.7818 per share, with individual trades ranging from $26.78 to $26.79. Following these transactions, Yea directly owns 229,918 shares of KalVista common stock.

KalVista Pharmaceuticals' chief development officer Christopher Yea reported routine equity activity involving restricted stock units and a small share sale. He exercised 3,125 restricted stock units, receiving an equal number of common shares for no cash consideration. To cover tax withholding from this RSU vesting, he sold 1,966 common shares in an open-market "sell to cover" transaction that the company states was not discretionary. After these transactions, Yea directly holds 229,918 shares of common stock. His RSU award totals 25,000 units, with 1/16 of the grant vesting on each quarterly anniversary of the August 22, 2024 vesting commencement date, contingent on continued service.

KalVista Pharmaceuticals’ Chief Commercial Officer Nicole Sweeny reported routine equity compensation activity. On May 22, 2026, she exercised 5,000 Restricted Stock Units (RSUs), each converting into one share of common stock for no cash cost. A Form 4 footnote explains that on May 26, 2026 she sold 1,489 common shares at $26.7778 per share solely to cover tax withholding obligations through a “sell to cover” transaction, which the company notes was not a discretionary sale. After these transactions, she directly holds 59,291 shares of common stock and 40,000 RSUs that continue to vest quarterly, subject to continued service.

KalVista Pharmaceuticals’ Chief Medical Officer, Paul K. Audhya, reported routine equity compensation activity and a related tax sale. On May 22, 2026, he exercised 5,000 Restricted Stock Units, receiving 5,000 shares of common stock for no cash consideration as part of RSU vesting.

On May 26, 2026, he sold 2,239 shares of common stock at $26.7778 per share in a “sell to cover” transaction to satisfy tax withholding obligations, which the filing states was not a discretionary trade. Following these transactions, he directly held 150,260 shares of common stock and 40,000 RSUs.

KalVista Pharmaceuticals’ CEO Benjamin L. Palleiko reported RSU vesting and a related tax sale. On May 21, 2026, 23,250 Restricted Stock Units converted into an equal number of common shares for no cash payment. On May 22, 2026, he sold 10,926 common shares at an average price of $26.7844 per share to cover tax withholding obligations from this RSU vesting, a non-discretionary “sell to cover” transaction. Following these transactions, he directly holds 479,989 common shares and 255,750 RSUs, so the tax-related sale represents a small portion of his overall equity position.

KalVista Pharmaceuticals Chief Commercial Officer Nicole Sweeny reported routine equity compensation activity. On May 21, 2026, 6,250 restricted stock units converted into the same number of shares of common stock at no cost upon vesting. Each RSU represents a right to receive one share.

On May 22, 2026, she sold 1,861 shares of common stock at an average price of $26.7844 per share. According to the disclosure, this sale was executed solely to cover tax withholding obligations from the RSU vesting as a “sell to cover” transaction and was not a discretionary trade. After these transactions, Sweeny directly holds 55,780 shares of KalVista common stock.

KalVista Pharmaceuticals chief development officer Christopher Yea reported routine equity compensation activity. He exercised 3,750 restricted stock units (RSUs), receiving the same number of common shares for no cash cost. Following this, he sold 2,358 common shares at $26.7844 per share.

According to the footnotes, this sale was a non-discretionary “sell to cover” transaction to fund tax withholding tied to the RSU vesting, rather than an elective sale. After these transactions, Yea directly holds 228,759 common shares and 41,250 RSUs that continue to vest quarterly, indicating he retains nearly all of his equity exposure.

KalVista Pharmaceuticals Chief Medical Officer Paul K. Audhya reported routine equity compensation-related transactions. On May 21, 2026, he exercised 6,250 restricted stock units (RSUs), receiving 6,250 shares of Common Stock at $0.00 per share upon settlement.

On May 22, 2026, he sold 2,685 Common Stock shares at an average price of $26.7844 per share solely to cover tax withholding obligations through a "sell to cover" transaction, which the filing states was not a discretionary sale. After these transactions, he directly owned 147,499 Common Stock shares and 68,750 RSUs representing contingent rights to receive an equal number of shares over time, subject to vesting.

KalVista Pharmaceuticals Chief Financial Officer Brian Piekos reported routine equity compensation activity and a tax-related share sale. On May 21, 2026, 5,000 restricted stock units converted into 5,000 shares of common stock for no cash consideration. On May 22, 2026, 1,489 of those shares were sold at $26.7844 per share solely to cover tax withholding obligations under a “sell to cover” arrangement, which the company states was not a discretionary transaction. After these events, Piekos directly held 21,661 shares of common stock, and his reported restricted stock unit balance was 55,000 units.

KalVista Pharmaceuticals chief development officer Christopher Yea reported routine equity compensation activity. On May 17, 2026, 1,774 restricted stock units vested and were converted into the same number of common shares for no cash consideration. On May 18, 2026, 1,108 common shares were sold at $26.76 per share solely to cover tax withholding obligations through a “sell to cover” arrangement, described as a non-discretionary transaction. After these transactions, Yea directly holds 227,367 shares of KalVista common stock.

KalVista Pharmaceuticals, Inc. Chief Medical Officer Paul K. Audhya reported routine equity compensation activity involving restricted stock units (RSUs) and a small related sale. On May 17, 2026, he exercised RSUs covering 2,419 shares of common stock at $0.00 per share, converting all of those RSUs into common shares.

On May 18, 2026, he sold 1,032 shares of common stock at an average price of $26.76 per share. A footnote explains this was a "sell to cover" transaction to satisfy tax withholding obligations tied to the RSU vesting, and is described as not a discretionary trade. Following these transactions, he directly holds 143,934 shares of KalVista common stock.

KalVista Pharmaceuticals CEO Benjamin L. Palleiko reported routine equity transactions tied to RSU vesting. On May 17, he exercised 2,419 restricted stock units, receiving the same number of common shares at no cost. On May 18, he sold 1,129 common shares at $26.76 per share to cover tax withholding obligations, according to the footnotes, which state this was a non-discretionary “sell to cover” transaction. After these moves, he directly holds 467,665 common shares.

KalVista Pharmaceuticals, Inc. chief executive Benjamin L. Palleiko reported routine equity compensation activity and related tax sales. On May 11, 2026, he exercised 7,120 restricted stock units, receiving an equal number of common shares for no cash cost as the units vested.

On May 12, 2026, he sold 3,322 common shares at $26.71 per share to cover tax withholding obligations from this vesting. A footnote explains this “sell to cover” transaction did not represent a discretionary sale decision. After these transactions, he directly owned 466,375 common shares, with additional RSUs remaining outstanding.

KalVista Pharmaceuticals chief medical officer Paul K. Audhya reported routine equity compensation activity and a related tax sale. On April 16, 6,250 restricted stock units vested into the same number of common shares at no cost, as part of a scheduled RSU vesting plan. A total of 2,686 common shares were then sold at an average price of $20.2163 solely to cover tax withholding obligations through a non-discretionary sell-to-cover arrangement. After these transactions, he directly holds 142,547 shares of common stock and 93,750 unvested RSUs that continue to vest quarterly, subject to continued service.

KalVista Pharmaceuticals Chief Commercial Officer Nicole Sweeny reported routine equity compensation activity and a related tax sale. On April 16, 2026, 6,250 restricted stock units converted into an equal number of common shares at no cost, reflecting RSU vesting. On April 17, 2026, 1,862 common shares were sold at $20.2163 per share solely to cover tax withholding obligations in a non-discretionary “sell to cover” transaction. After these transactions, Sweeny directly held 51,391 shares of KalVista common stock. The RSU award vests in 16 equal quarterly installments starting on April 16, 2026, subject to continued service.

KalVista Pharmaceuticals Chief Financial Officer Brian Piekos reported routine equity compensation activity. On April 16, 2026, 6,250 restricted stock units (RSUs) converted into the same number of common shares for no cash consideration, reflecting scheduled vesting. On April 17, 2026, he sold 1,862 common shares at $20.2163 per share in an open-market transaction specifically to cover tax withholding obligations from the RSU vesting, described as a nondiscretionary “sell to cover” sale. After these transactions, he directly held 18,150 common shares, and 93,750 RSUs remained outstanding, which continue to vest quarterly in 1/16 increments starting April 16, 2026, subject to continued service.

KalVista Pharmaceuticals CEO Benjamin L. Palleiko reported routine equity compensation activity and a related tax sale. On April 16, 2026, restricted stock units vested and were settled into 20,312 shares of Common Stock at $0.00 per share, reflecting a compensation-related share delivery. To cover tax withholding obligations from this RSU vesting, he then sold 9,550 shares of Common Stock at an average price of $20.2163 per share on April 17, 2026 in a "sell to cover" transaction described as non-discretionary. Following these transactions, he holds 462,577 Common Stock shares directly.

KalVista Pharmaceuticals’ major shareholder funds reported open-market sales of 214,631 shares of Common Stock. The transactions were executed on March 25–26 at prices between approximately $16.95 and $19.12 per share through entities affiliated with Venrock Healthcare Capital Partners.

After these sales, the affiliated funds continue to hold about 5,089,354 shares indirectly. The filing clarifies that management entities and individuals associated with these funds may be deemed to beneficially own these securities only to the extent of any indirect pecuniary interest.

KalVista Pharmaceuticals CEO Benjamin L. Palleiko reported routine equity compensation activity and a related tax sale. On March 6, 2026, he exercised 15,625 Restricted Stock Units (RSUs), receiving an equal number of KalVista common shares for no cash consideration. The RSUs vest in 16 equal quarterly installments starting June 6, 2024, subject to continued service. On March 9, 2026, he sold 6,693 common shares at a weighted average price of $16.0814 per share solely to cover tax withholding obligations from the RSU vesting, described as a non-discretionary “sell to cover” transaction. After these transactions, he holds 451,815 common shares directly and 125,001 RSUs, giving him a substantial ongoing equity stake.

KalVista Pharmaceuticals chief medical officer Paul K. Audhya reported a mix of equity award vesting and tax-related share sales. He exercised and settled restricted stock units (RSUs) into 6,250 and 5,000 shares of common stock at no cost on separate days, reflecting routine equity compensation vesting where each RSU converts into one share.

To cover tax withholding from these RSU settlements, he sold 5,354 shares of common stock in an open-market "sell to cover" transaction at a weighted average price of $15.5668 per share, described as non-discretionary. After these transactions, he held 138,983 shares of common stock directly, with RSU awards continuing to vest in equal sixteenth installments on each quarterly anniversary of the vesting commencement date.

KalVista Pharmaceuticals CEO Benjamin L. Palleiko reported a mix of RSU vesting and tax-related share sales. On February 21, 2026, he acquired 23,250 shares of Common Stock at $0.00 per share through the settlement of Restricted Stock Units, each RSU converting into one common share at no cost.

On February 23, 2026, he sold 10,034 shares of Common Stock at a weighted average price of $15.5668 per share, in transactions ranging from $15.5253 to $15.566982. According to the disclosure, this sale was a mandatory “sell to cover” to satisfy tax withholding obligations tied to the RSU vesting, and was not a discretionary trade.

KalVista Pharmaceuticals’ Chief Development Officer Christopher Yea reported RSU vesting, share issuance, and a related tax sale of common stock. On February 21 and 22, RSUs covering a total of 6,875 restricted stock units were exercised into the same number of common shares for no cash consideration.

Following these conversions, Yea conducted an open‑market "sell to cover" transaction on February 23, disposing of 4,347 common shares at a weighted average price of $15.5668 per share solely to satisfy tax withholding obligations tied to the RSU vesting. After these transactions, he held 226,701 common shares and 28,125 RSUs directly, with future RSU vesting scheduled in quarterly installments.

KalVista Pharmaceuticals Chief Commercial Officer Nicole Sweeny reported RSU vesting and related share movements. She acquired 6,250 and 5,000 shares of common stock on derivative exercises of restricted stock units at a price of $0.0000 per share. Each RSU represents a right to receive one share of common stock, with 1/16th of the award vesting on each quarterly anniversary of the vesting commencement date, subject to continued service.

On a separate transaction, she sold 3,975 shares of common stock in an open-market sale at a weighted average price of $15.5668 per share, in multiple trades between $15.5101 and $15.566982. The filing states this sale was a "sell to cover" to satisfy tax withholding obligations arising from RSU vesting and was not a discretionary transaction. Following these transactions, she directly held 47,003 shares of KalVista common stock.

KalVista Pharmaceuticals Chief Financial Officer Brian Piekos reported RSU vesting and a related tax sale. On February 21, 2026, he acquired 5,000 shares of Common Stock at $0.00 per share through the exercise and settlement of 5,000 Restricted Stock Units, each RSU converting into one share for no consideration. On February 23, 2026, he sold 1,767 shares of Common Stock in open-market transactions at a weighted-average price of $15.5668 per share to cover tax withholding obligations under a non-discretionary sell-to-cover arrangement. Following these transactions, he directly held 13,762 shares of Common Stock and 60,000 RSUs.

KalVista Pharmaceuticals chief executive officer Benjamin L. Palleiko reported routine equity compensation activity. On February 17, he exercised 2,419 restricted stock units, each converting into one share of common stock for no cash consideration, and his common stock holdings increased to 430,705 shares.

On February 18, he sold 1,038 common shares at $15.00 per share solely to cover tax withholding obligations related to the RSU vesting, a non‑discretionary “sell to cover” transaction. After this tax sale, he directly owned 429,667 common shares and 2,419 RSUs subject to continued vesting in equal quarterly installments.

KalVista Pharmaceuticals chief medical officer Paul K. Audhya reported routine equity transactions linked to restricted stock units (RSUs). He sold 1,163 shares of common stock at $15.00 per share to cover tax withholding obligations arising from RSU vesting in a non-discretionary sell-to-cover trade.

In connection with this, 2,419 RSUs were exercised and converted into 2,419 shares of common stock for no cash consideration, with each RSU representing one share upon settlement. The RSUs vest in equal sixteenth installments on each quarterly anniversary of the vesting commencement date, subject to continued service.

KalVista Pharmaceuticals chief development officer Christopher Yea reported RSU vesting and related share activity. On February 17, 2026, 1,774 restricted stock units were converted into 1,774 shares of common stock for no cash consideration. On February 18, 2026, 1,109 common shares were sold at $15.00 per share solely to cover tax withholding obligations under a pre-arranged “sell to cover” and were not a discretionary sale.

Palleiko Benjamin L reported multiple insider transaction types in a Form 4 filing for KALV. The filing lists transactions totaling 17,594 shares at a weighted average price of $15.70 per share. Following the reported transactions, holdings were 428,286 shares.

KalVista Pharmaceuticals, Inc. reported that its Chief Operations Officer, Arif Bilal, received a grant of 49,000 restricted stock units (RSUs) on January 16, 2026. Each RSU represents a contingent right to receive 1 share of KalVista common stock upon settlement for no cash consideration.

The RSUs vest in equal installments over four years. Specifically, 1/16 of the total RSUs will vest on each quarterly anniversary of the vesting commencement date, starting May 22, 2026, as long as Bilal’s service with the company does not terminate. Following this grant, he beneficially owns 49,000 RSUs directly.

KalVista Pharmaceuticals reported that its Chief Commercial Officer, Nicole Sweeny, received an equity award in the form of restricted stock units. On January 16, 2026, she was granted 100,000 restricted stock units (RSUs), each representing the right to receive one share of KalVista common stock for no cash payment upon settlement. The RSUs are scheduled to vest in equal installments, with 1/16 of the total amount vesting on each quarterly anniversary of the vesting commencement date, beginning on May 22, 2026, as long as her service with the company continues. Following this grant, she holds 100,000 derivative securities directly in the form of RSUs.

KalVista Pharmaceuticals reported an equity award for its Chief Financial Officer, Brian Piekos. On January 16, 2026, he received 100,000 restricted stock units (RSUs), each representing the right to receive one share of KalVista common stock for no cash consideration upon settlement.

The RSUs are scheduled to vest in equal installments, with 1/16 of the total vesting on each quarterly anniversary of the vesting commencement date starting on May 22, 2026, as long as his service with the company continues. Following this grant, he beneficially owns 100,000 derivative securities in the form of RSUs, held directly.

KalVista Pharmaceuticals’ chief medical officer receives new equity award. Paul K. Audhya, the company’s Chief Medical Officer, reported a grant of 100,000 restricted stock units on January 16, 2026. Each RSU represents the right to receive 1 share of KalVista common stock upon settlement for no cash payment. The RSUs will vest over four years, with 1/16 of the total units vesting on each quarterly anniversary of the vesting commencement date, starting on May 22, 2026, as long as his service with the company continues. Following this grant, he beneficially owns 100,000 derivative securities directly.

KalVista Pharmaceuticals, Inc. reported that its Chief Executive Officer and director, Benjamin L. Palleiko, received a grant of 325,000 restricted stock units (RSUs) on January 16, 2026. Each RSU represents a contingent right to receive one share of KalVista common stock for no cash consideration when the units settle.

According to the vesting terms, 1/16 of the RSUs will vest on each quarterly anniversary of the vesting commencement date, starting on May 22, 2026, as long as his service with the company does not terminate. Following this award, Palleiko directly holds 325,000 derivative securities in the form of RSUs.

KalVista Pharmaceuticals (KALV) reported an insider equity transaction by its Chief Development Officer. On 11/20/2025, the officer exercised an employee stock option to acquire 87,390 shares of common stock at an exercise price of $0.0043 per share, coded as transaction type "M" (option exercise). After this transaction, the officer directly beneficially owned 220,964 shares of KalVista common stock. The related employee stock option, which was 100% vested, was fully exercised and no derivative securities remained beneficially owned.

KalVista Pharmaceuticals, Inc. insider activity: the company’s Chief Executive Officer and director reported routine equity award activity. On 11/17/2025, the reporting person acquired 9,364 shares of common stock through the vesting and settlement of restricted stock units (coded “M”), increasing directly held common shares to 408,345. On 11/18/2025, 4,466 shares of common stock were sold at a weighted average price of $14.4794 per share, leaving 403,879 shares of common stock directly owned.

The sale was made to cover tax withholding obligations arising from RSU vesting under a “sell to cover” arrangement and is described as non-discretionary. Related RSU awards provided common shares at no cash exercise price, with portions vesting in equal installments on quarterly anniversaries of their respective vesting commencement dates, subject to continued service.

KalVista Pharmaceuticals, Inc. insider trading report: The company’s Chief Development Officer filed a Form 4 detailing routine equity award activity. On 11/17/2025, the officer acquired 4,205 shares of KalVista common stock following the vesting and settlement of restricted stock units (RSUs), which convert to common stock on a one-for-one basis for no cash consideration. On 11/18/2025, 2,683 shares were sold in a broker-assisted “sell to cover” transaction at a weighted average price of $14.4794 per share to satisfy tax withholding obligations tied to the RSU vesting, described as non-discretionary. After these transactions, the officer beneficially owned 133,574 shares of KalVista common stock, held directly.

KalVista Pharmaceuticals' (KALV) Chief Medical Officer reported equity activity involving restricted stock units and related share sales. On 11/17/2025, 6,447 shares of common stock were acquired through the vesting and settlement of restricted stock units, increasing direct holdings to 128,952 shares. On 11/18/2025, 3,075 shares were sold at a weighted average price of $14.4795 per share to cover tax withholding obligations from the RSU vesting, a non-discretionary "sell to cover" transaction, leaving 125,877 shares directly owned.

The filing also shows RSU awards converting into 2,419 and 4,028 shares of common stock at a conversion price of $0 per RSU. One RSU grant vests in 1/16th increments each quarterly anniversary of its vesting commencement date, and another in 1/12th quarterly increments, in each case conditioned on continued service.